Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Change in Inventory (2016 - 2025)

Dexcom (DXCM) has disclosed Change in Inventory for 16 consecutive years, with $17.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Inventory rose 154.43% to $17.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $63.7 million, a 613.71% increase, with the full-year FY2025 number at $63.7 million, up 613.71% from a year prior.
  • Change in Inventory was $17.8 million for Q4 2025 at Dexcom, down from $33.6 million in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $78.6 million in Q3 2023 to a low of -$32.7 million in Q4 2024.
  • A 5-year average of $18.3 million and a median of $18.2 million in 2025 define the central range for Change in Inventory.
  • Peak YoY movement for Change in Inventory: plummeted 223.96% in 2022, then surged 5136.36% in 2023.
  • Dexcom's Change in Inventory stood at $6.0 million in 2021, then plummeted by 195.0% to -$5.7 million in 2022, then skyrocketed by 1135.09% to $59.0 million in 2023, then crashed by 155.42% to -$32.7 million in 2024, then surged by 154.43% to $17.8 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Change in Inventory are $17.8 million (Q4 2025), $33.6 million (Q3 2025), and $18.5 million (Q2 2025).